Randomised phase 3 trial: tegoprazan, a novel potassium-competitive acid blocker, vs. esomeprazole in patients with erosive oesophagitis.
Kwang Jae LeeByoung-Kwan SonGwang Ha KimHye Kyung JungHwoon Yong JungIl-Kwun ChungIn-Kyung SungJin Il KimJong Hyeok KimJoon Seong LeeJoong Goo KwonJung Ho ParkKyu Chan HuhKyung Sik ParkMoo In ParkNa Young KimOh Young LeeSam Ryong JeeSang Kil LeeSei Jin YounSung Kook KimSoo Teik LeeSu Jin HongSuck-Chei ChoiTae Nyeun KimYoung Hoon YounHyo Ju ParkMin Ja KangChi Hye ParkBong Tae KimSangjun YounGeun Seog SongPoong Lyul RheePublished in: Alimentary pharmacology & therapeutics (2019)
Once daily administration of tegoprazan 50 or 100 mg showed non-inferior efficacy in healing EE and tolerability to that of esomeprazole 40 mg.